Cited by 12COVID-19 Clinical Research StudiesGenetic Associations and EpidemiologyThyroid Disorders and Treatments

Heterozygote advantage of the type II deiodinase thr92Ala polymorphism on intrahospital mortality of COVID-19

Open access
de Lima Beltrão, Fabyan Esberard, de Almeida Beltrão, Daniele Carvalhal, Carvalhal, Giulia, de Lima Beltrão, Fabricia Elizabeth, de Souza Braga Filho, Jair, de Brito Oliveira, Jocyel, de Jesus, Joice dos Santos, Machado, Gabriel Jeferson Rodríguez +9 more·2022·The Journal of Clinical Endocrinology & Metabolism

Abstract

CONTEXT: The type 2 deiodinase and its Thr92Ala-DIO2 polymorphism have been linked to clinical outcomes in acute lung injury and pulmonary fibrosis. OBJECTIVE: Our objectives were to evaluate were cumulative mortality during admission according to Thr92Ala-DIO2 polymorphism. METHODS: Here we conducted an observational, longitudinal, and prospective cohort study to investigate a possible association between the Thr92Ala-DIO2 polymorphism and intrahospital mortality from COVID-19 in adult patients admitted between June and August 2020. Blood biochemistry, thyroid function tests, length of stay, comorbidities, complications, and severity scores were also studied according to Thr92Ala-DIO2 polymorphism. RESULTS: In total, 220 consecutive patients (median age 62; 48-74 years) were stratified into 3 subgroups: Thr/Thr (n = 79), Thr/Ala (n = 119), and Ala/Ala (n = 23). While the overall mortality was 17.3%, the lethality was lower in Ala/Thr patients (12.6%) than in Thr/Thr patients (21.7%) or Ala/Ala patients (23%). The heterozygous genotype (Thr/Ala) was associated with a 47% reduced risk of intrahospital mortality whereas univariate and multivariate logistic regression adjusted for multiple covariates revealed a reduction that ranged from 51% to 66%. The association of the Thr/Ala genotype with better clinical outcomes was confirmed in a metanalysis of 5 studies, including the present one. CONCLUSION: Here we provide evidence for a protective role played by Thr92Ala-DIO2 heterozygosity in patients with COVID-19. This protective effect follows an inheritance model known as overdominance, in which the phenotype of the heterozygote lies outside the phenotypical range of both homozygous.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/clinem/dgac075

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 66 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

  1. [16]16. Schilling JU, Zimmermann T, Albrecht S, Zwipp H, Saeger HD. Low T3 syndrome in multiple trauma patients—a phenomenon or important pathogenetic factor? Med Klin. 1999;94(Suppl 3):66-69. [DOI] [PubMed] [Google Scholar]
  2. [49]49. Carrington M, Nelson GW, Martin MP, et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science. 1999;283(5408):1748-1752. [DOI] [PubMed] [Google Scholar]
  3. [63]63. Kim HJ, Jeong JS, Kim SR, Park SY, Chae HJ, Lee YC. Inhibition of endoplasmic reticulum stress alleviates lipopolysaccharide-induced lung inflammation through modulation of NF-κB/HIF-1α signaling pathway. Sci Rep. 2013;3(1):1-10. [DOI] [PMC free article] [PubMed] [Google Scholar]

Cited by

Sorted by citations

Authors
de Lima Beltrão, F. E., de Almeida Beltrão, D. C., Carvalhal, G., de Lima Beltrão, F. E., de Souza Braga Filho, J., de Brito Oliveira, J., de Jesus, J. D. S., Machado, G. J. R., dos Santos Silva, H., Teixeira, H. M. P., Rodrigues, J. L., de Figueiredo, C. A. V., dos Santos Costa, R., Hecht, F., Bianco, A. C., da Conceição Rodrigues Gonçalves, M., & Ramos, H. E.
Affiliations
  • Lauro Wanderley University Hospital, Federal University of Paraíba, João Pessoa, Paraíba, Brazil
  • University Center of João Pessoa – UNIPE, João Pessoa, PB, Brazil
  • Universidade Federal de Campina Grande (BR)
  • Bioregulation Department, Health and Science Institut, Federal University of Bahia, Salvador, Bahia, Brazil
  • Universidade Federal da Bahia (BR)
  • Laboratory of Immunopharmacology and Molecular Biology, Health Sciences Institute, Federal University of Bahia, Brazil
  • The Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
  • University of Chicago (US)
  • Post-Graduation Program in Nutritional Sciences, Department of Nutrition, Center for Health Sciences, Federal University of Paraíba, João Pessoa, Paraíba, Brazil
Corresponding author
Ramos, Helton Estrela
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2022-02-09
Volume
107
Issue
6
Pages
e2488-e2501
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W4211020255
Cited by
12
References
66
Citations by year
2025: 3 · 2024: 3 · 2023: 2 · 2022: 4
FWCI
1.47
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK065055)
Topics
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
Keywords
type 2 deiodinase, DIO2, COVID-19 pandemic, in-hospital mortality, overdominance, genetic susceptibility, thyroid hormone metabolism, SARS-CoV-2
MeSH terms
COVID-19, Iodothyronine Deiodinase Type II, Heterozygote, Humans, Iodide Peroxidase, Longitudinal Studies, Prospective Studies, Hospital Mortality, Polymorphism, Single Nucleotide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review